These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32658554)

  • 21. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G
    Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
    Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
    Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):73-77. PubMed ID: 35912560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R; Testa G; Assogna F; De Stefano N
    CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon.
    Matni M; Yamout B; Koussa S; Khamis C; Fleifel L; Sharifi S; Mohamed O
    Mult Scler Relat Disord; 2022 Nov; 67():104169. PubMed ID: 36150262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
    Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
    Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
    Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D; Müller B; Übler S
    Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
    Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
    Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri D; Pesch VV; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H;
    Neurodegener Dis Manag; 2023 Aug; 13(4):215-221. PubMed ID: 37287269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
    Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
    Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.